Scancell Release: Collaboration With ImmuneRegen BioSciences, Inc. Yields Positive Results in Cancer Vaccine Studies

Published: Sep 07, 2010

NOTTINGHAM, England--(BUSINESS WIRE)--Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®’s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell’s cancer vaccines.

Back to news